NOCTURNE随机试验:两种托伐普坦制剂比较
NOCTURNE试验为2期随机双盲安慰剂对照研究,纳入了177例常染色体显性多囊肾病患者,比较每日一次改良释放托伐普坦(MR 50mg或80mg)与每日两次速释托伐普坦(IR 60/30mg)及安慰剂的短期疗效和耐受性。主要终点为第3周总肾脏体积(TKV)较基线的百分比变化:托伐普坦组(MR+IR汇总)平均下降2.07%,MR 80mg组下降2.55%,MR 50mg组下降2.46%,均显著优于安慰剂(0.09%;每个比较P<0.02),而IR 60/30mg组下降1.17%(P=0.24)未达显著性。所有托伐普坦方案均伴有利尿相关不良事件,但患者报告结局显示对健康相关生活质量影响较小。结论认为MR与IR制剂短期疗效、耐受性和安全性相似,对生活质量影响低,但长期疗效因随访时间短而受限。
要点
- 第3周TKV下降:MR 80mg为2.55%,MR 50mg为2.46%,IR 60/30mg为1.17%,安慰剂为0.09%。
- MR 50mg和80mg及MR+IR汇总组TKV下降均显著优于安慰剂(P<0.02),IR 60/30mg未达显著(P=0.24)。
- 所有托伐普坦方案均有利尿相关不良事件,但生活质量影响较小。
核心结论
- 托伐普坦MR与IR制剂短期疗效、耐受性和安全性相似,对多种生活质量指标影响低。
- 长期疗效结论受随访时间短的限制。
研究设计与样本
- 2期多中心、随机(1:1:1:1)、安慰剂对照、双盲、安慰剂掩蔽、平行组研究(NCT01451827),共纳入177例受试者,治疗8周。
- 比较托伐普坦MR 50mg每日一次、MR 80mg每日一次、IR 60/30mg每日分次给药与安慰剂。
- 主要终点为第3周TKV较基线的百分比变化。
主要发现
- 第3周TKV平均百分比下降:MR+IR汇总组-2.07%,MR 80mg组-2.55%,MR 50mg组-2.46%,安慰剂组0.09%;每个与安慰剂比较P<0.02。
- IR 60/30mg组TKV下降-1.17%(P=0.24),未达统计学显著性。
- 所有托伐普坦方案均伴有利尿相关不良事件。
- ADPKD特异性和通用患者报告结局评估显示,不同剂量对总体健康相关生活质量影响较小(与安慰剂相比)。
关键数值与推荐
- 主要终点:第3周TKV较基线百分比变化。
- MR 50mg和80mg及MR+IR汇总组TKV下降均显著优于安慰剂(P<0.02);IR 60/30mg组P=0.24。
临床怎么用
- 对于ADPKD患者,托伐普坦MR每日一次与IR每日两次短期疗效和耐受性相似,可根据给药便利性选择。
- 需关注利尿相关不良事件,但短期生活质量影响较小。
局限性
- 随访时间短(8周),长期疗效结论受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tolvaptan, a treatment for autosomal dominant polycystic kidney disease (ADPKD), inhibits vasopressin V2 receptor signaling, which causes aquaretic adverse events (AAEs). The short-term efficacy and tolerability of a once-daily, modified-release (MR) formulation was assessed relative to the twice-daily, immediate-release (IR) formulation. METHODS: This Phase 2 multicenter, randomized (1:1:1:1), placebo-controlled, double-blind, placebo-masked, parallel-group study (NCT01451827) compared tolvaptan MR 50 mg once daily or tolvaptan MR 80 mg once daily with tolvaptan IR 60/30 mg daily split dose and placebo over 8 weeks in 177 subjects. The primary endpoint was percent change from baseline in total kidney volume (TKV) at week 3. Other endpoints included tolerability, assessed by adverse events and quality of life (QOL) measures. RESULTS: Mean percentage decreases in TKV at week 3 were observed for the pooled group of all (MR+IR) tolvaptan-treated subjects (-2.07%), tolvaptan MR 80 mg (-2.55%), and tolvaptan MR 50 mg (-2.46%) versus placebo (0.09%; P < 0.02 for each comparison with placebo), whereas the decrease with tolvaptan IR 60/30 mg (-1.17%; P = 0.24) did not reach significance. All tolvaptan regimens were associated with AAEs, but scores on ADPKD-specific and generic patient-reported outcome assessments showed little impact based on dosage on overall health-related QOL versus placebo. CONCLUSION: Tolvaptan MR and tolvaptan IR demonstrated similar short-term efficacy, tolerability, and safety, with low impact on multiple measures of QOL. Conclusions regarding long-term efficacy are limited by the short duration of follow-up.
引用
- Perrone RD, Chapman AB, Oberdhan D, et al. The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. Kidney Int Rep. 2020. PMID: 32518862. doi:10.1016/j.ekir.2020.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。